INT128451

Context Info Confidence 0.50 First Reported 2005 Last Reported 2010 Negated 0 Speculated 1 Reported most in Body Documents 2 Total Number 4 Disease Relevance 1.28 Pain Relevance 0.67

oxidoreductase activity (RNLS) extracellular region (RNLS)

RNLS (Homo sapiens)

Pain Link Frequency Relevance Heat monoamine 5 100.00 Catecholamine 45 96.16 fluoxetine 1 94.84 antagonist 1 94.38 ischemia 54 89.12 imagery 6 80.64 Serotonin 3 75.00 tolerance 3 16.76 Angina 3 5.00 Parenteral administration 3 5.00

Disease Link Frequency Relevance Heat Coronary Artery Disease 36 92.24 Cv Unclassified Under Development 48 89.12 Coronary Heart Disease 48 88.04 Left Ventricular Hypertrophy 18 76.20 Increased Venous Pressure Under Development 3 75.00 Obesity 12 71.24 Hypertension 17 64.36 Stress 15 43.84 Cardiovascular Disease 3 43.20 Nicotine Addiction 6 37.40

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Future studies should be aimed at determining whether there is a potential therapeutic role for renalase replacement in persons at high risk of cardiovascular morbidity and mortality.

Spec (whether) Positive_regulation (role) of renalase

1) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2958117 Disease Relevance 0.35 Pain Relevance 0.13

Renalase is a FAD dependent oxidoreductase, which uses NADH as a cofactor to reduce its FAD moiety.

Positive_regulation (dependent) of Renalase

2) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2958117 Disease Relevance 0.43 Pain Relevance 0.12

Data from the International HapMap Consortium has identified a single common non-synonymous single-nucleotide polymorphism in the human renalase gene that results in an aspartic acid to glutamic acid substitution at codon 37 (Glu37Asp) in the flavin-adenine dinucleotide-binding site.

Positive_regulation (results) of renalase gene

3) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2958117 Disease Relevance 0.24 Pain Relevance 0.09

Treatment with SB224289 (selective antagonist of 5-HT1B), fluoxetine (SERT inhibitor), SERT RNA-interference, and iproniazid (monoamine oxidase-A inhibitor), blocked 5-HT-induced S100A4/Mts1. 5-HT signaling mediated phosphorylation (p) of extracellular signal-regulated kinase 1/2 (pERK1/2), but pERK1/2 nuclear translocation depended on SERT, monoamine oxidase activity, and reactive oxygen species.

Positive_regulation (depended) of monoamine oxidase associated with antagonist, monoamine and fluoxetine

4) Confidence 0.06 Published 2005 Journal Circ. Res. Section Abstract Doc Link 16002749 Disease Relevance 0.27 Pain Relevance 0.34

General Comments

This test has worked.